Technology
AI reveals potential in Alzheimer’s drug trial
An AI model uncovered a 46 per cent drop in cognitive decline among early-stage Alzheimer’s patients when reanalysing data from a previously unsuccessful drug trial.
Scientists used artificial intelligence to split trial participants into two groups based on how quickly their condition was progressing. The reassessment revealed the drug slowed symptoms in those with early-stage, slow-progressing mild cognitive impairment – a condition that can develop into Alzheimer’s disease.
The findings suggest AI could help improve patient selection for clinical trials, potentially reducing the cost of developing new medicines. The model was three times more accurate than standard clinical assessments, which typically rely on memory tests, MRI scans and blood tests.
Developed at the University of Cambridge, the AI system predicts whether and how fast someone at the early stages of cognitive decline will develop Alzheimer’s. It is now being supported by Health Innovation East England to help bring the technology into clinical care.
Researchers applied the model to data from a completed trial of a drug that had failed to show benefits in the overall population. The drug cleared beta amyloid – a protein linked to early Alzheimer’s – in all patients. But only those in the slow-progressing group showed symptom improvements, highlighting the need to target treatment at the right stage.
“Promising new drugs fail when given to people too late, when they have no chance of benefiting from them. With our AI model, we can finally identify patients precisely, and match the right patients to the right drugs. This makes trials more precise, so they can progress faster and cost less, turbocharging the search for a desperately-needed precision medicine approach for dementia treatment,” said Professor Zoe Kourtzi, senior author from the University of Cambridge’s department of psychology.
“Our AI model gives us a score to show how quickly each patient will progress towards Alzheimer’s disease. This allowed us to precisely split the patients in the clinical trial into two groups – slow- and fast-progressing – so we could look at the effects of the drug on each group.”
Joanna Dempsey, principal advisor at Health Innovation East England, said: “This AI-enabled approach could have a significant impact on easing NHS pressure and costs in dementia care by enabling more personalised drug development—identifying which patients are most likely to benefit from treatment, resulting in faster access to effective medicines and targeted support for people living with dementia.”
These drugs are not designed to cure Alzheimer’s, but to slow cognitive decline and help patients maintain their condition for longer.
Dementia is the UK’s leading cause of death and one of the top global causes of mortality. It costs US$1.3 trillion each year worldwide, and the number of cases is expected to triple by 2050.
Despite decades of research and over US$43bn invested in drug development, the failure rate for new treatments remains above 95 per cent. One key barrier is the wide variation in symptoms and progression among patients.
While some new dementia drugs have been approved in the US, concerns about side effects and limited cost-effectiveness have so far delayed their adoption in the NHS.
Understanding individual differences in disease progression is critical for developing effective treatments. Alzheimer’s is a complex disease, and while drugs exist, they don’t work for every patient.
“AI can guide us to the patients who will benefit from dementia medicines, by treating them at the stage when the drugs will make a difference, so we can finally start fighting back against these cruel diseases. Making clinical trials faster, cheaper and better, guided by AI, has strong potential to accelerate the discovery of new precise treatments for individual patients, reducing side effects and costs for health care services,” said Kourtzi.
She added: “Like many people, I have watched hopelessly as dementia stole a loved one from me. We’ve got to accelerate the development of dementia medicines. Over £40bn has already been spent over thirty years of research and development – we can’t wait another thirty years.”
A new brain health collaboratory from Cognito and Ochsner aims to test new ways of treating cognitive decline and Alzheimer’s disease.
The Brain Health Collaboratory is described as the Gulf South’s first statewide platform for non-invasive brain health innovation.
It will combine Cognito’s investigational Spectris technology with Ochsner’s clinical network to explore care models across urban and rural communities in the region.
Dr David Houghton, system chair of neurology at Ochsner Health, said: “This new collaboratory affords us the opportunity to pair emerging neurotechnology with real-world clinical care to better understand how we can slow cognitive decline, improve patients’ lives and open new therapeutic pathways for other neurological diseases in the future.”
At the centre of the initiative is Spectris, an investigational device for use at home that delivers synchronised light and sound stimulation through the brain’s natural sensory pathways.
The technology is designed to support healthy neural network activity and, according to its developers, has shown early promise in helping preserve brain structure and function in Alzheimer’s disease.
It received Breakthrough Device Designation from the US Food and Drug Administration in 2021 and is currently being evaluated in clinical trials.
The two organisations will also work on a Brain Health Index, a framework intended to track cognitive health, disease progression and treatment response in real-world care settings.
The programme will explore how Spectris could be integrated into clinical care models for patients experiencing cognitive decline.
Cambridge, Massachusetts-based Cognito Therapeutics describes itself as a late clinical-stage neurotechnology company focused on non-invasive neuroprotective therapies for neurodegenerative diseases.
Ochsner Health is the leading nonprofit healthcare provider in Louisiana, Mississippi and across the Gulf South, operating 47 hospitals and more than 370 health and urgent care centres.
The collaboratory will also explore ways to integrate the technology into programmes serving patients eligible for both Medicare and Medicaid, the US government health insurance schemes, where Alzheimer’s disease places a significant clinical and economic burden.
Christian Howell, chief executive officer of Cognito Therapeutics, said: “Ochsner’s reach across the Gulf South provides a unique opportunity to bring innovative brain health technologies to a broad patient population.
“Partnerships like this are essential to ensuring that new therapies can reach patients not just in major academic centres, but across entire healthcare systems that serve both urban and rural communities.
“Expanding access to patients is critical to generating real-world evidence and ultimately delivering new options for people living with Alzheimer’s disease.”
The Ochsner partnership is the second such collaboratory for Cognito, which launched its first in November 2025 with the West Virginia University Rockefeller Neuroscience Institute.
The company says it plans to build a broader network of collaboratories with health systems and academic medical centres to expand patient access and generate real-world evidence.
The Spectris technology may also have potential in a range of other neurological conditions, including Parkinson’s disease, multiple sclerosis, traumatic brain injury, stroke and addiction, according to the company.
However, it remains investigational and has not yet received regulatory approval.
A centenarian study by HLI and LEV Foundation will examine why some people live past 100 and remain healthier for longer.
The collaboration will study blood samples from centenarians and supercentenarians, people aged 100 and 110 or over, to explore the biology of exceptional longevity.
Researchers are trying to answer a central question in ageing science: why do individuals age at different rates?
The study will use multi-omic analysis, including genomics and proteomics, which examine genes and proteins, to identify biomarkers and biological pathways linked to exceptional longevity.
Wei-Wu He, executive chairman at HLI, said: “Centenarians and supercentenarians offer natural insights in human ageing.
“By applying our precision longevity platform to those who have achieved exceptional longevity, we can better understand how to preserve health in late life for everyone.
“The knowledge gained here has the potential to reshape how we approach aging and age-related disease.”
The organisations say these rare groups represent a unique biological resource.
Their blood samples may contain molecular and cellular information that helps explain why some people age more slowly and maintain good health for longer than the wider population.
Building on those analyses, the study is expected to provide new insights into the mechanisms behind exceptional longevity and differences in ageing.
Comparative analyses of exceptionally long-lived people and broader population cohorts will aim to identify key molecular features of extreme longevity and help lay the groundwork for future longitudinal studies.
Human Longevity, Inc. (HLI) and LEV Foundation announced the collaboration. HLI, founded in 2013 and based in South San Francisco, says it integrates genomics, artificial intelligence and multimodal diagnostics to extend human healthspan.
LEV Foundation, founded in 2022, is a California-based nonprofit focused on extending healthy human lifespan, with its flagship Robust Mouse Rejuvenation study series examining combinations of promising anti-ageing interventions.
The project is being spearheaded by Natalie S. Coles-de Grey, who the organisations say brings decades of expertise in the study of supercentenarians.
Both Coles-de Grey and LEVF’s president and chief science officer, Aubrey de Grey, are joining HLI’s scientific advisory board.
de Grey said: “I’m delighted that LEVF is partnering with HLI to further both organizations’ goals.
“There is so much to be learned, from the oldest old in our society, that will refine the preventative medicine for the chronic conditions of late life that HLI has pioneered.
“Such work is immensely complementary to LEVF’s focus on mice, and I’m sure that this collaboration will have synergy that will save many future lives.”
The organisations said findings from the study are expected to contribute to the growing field of longevity science and may inform the development of diagnostics, therapeutics and preventive strategies aimed at extending healthspan across the global population.
By Ruth Dixon, Programme Lead, Challenge Works
Humans are social creatures – connection to others is vital for good health and wellbeing.
Despite this, research conducted last year showed that almost one out of every four older individuals in the world feels lonely – a significant and saddening statistic.
Research has consistently shown that people who become socially isolated as they get older are more likely to develop dementia.
Furthermore, people who already have dementia tend to experience a faster decline of their symptoms when they are socially isolated.
This was particularly evident during COVID lockdowns when people with dementia were cut off from their social networks.
Faced with an aging population, we must ensure that people can continue to grow old with dignity, remain independent and stay connected with loved ones after a dementia diagnosis – something that artificial intelligence is helping to make possible.
Technology to combat social isolation
While there is no silver bullet to combat social isolation, there are technologies available that can help to support people to remain independent in their own home and maintain connections with their friends, family and community.
Doing so can help to preserve their dignity, identity and sense of purpose while reducing stress and anxiety through familiar surroundings.
It allows them to maintain daily routines and cognitive function for longer by living in a comfortable environment with known, consistent layouts.
Thanks to the rapidly evolving technological landscape, we are venturing far beyond basic solutions.
AI and machine learning enables innovators to support those living with dementia directly (not just their caregivers) and in turn, better mitigate the risk of social isolation – with more than three quarters (77 per cent) of family doctors believing this type of technology will help people with dementia to live longer.
Designing with and for people living with dementia
However, for dementia technology to be effective, it needs to be designed with, not just for, the end user.
MemoryAid is a fantastic example of a co-created solution.
Designed to be reminiscent of a traditional telephone, MemoryAid is a home assistant device that has been developed specifically for and with people living with dementia to help them make video calls and stay connected.
The touchscreens on everyday smartphones and tablets are not always designed with older users in mind.
Smartphones and tablets need to be kept charged and require dexterous movements, be it swiping, tapping or clicking small buttons to make or answer a call – a challenge for many people, let alone someone living with a neurodegenerative condition.
Rather than having to navigate a touchscreen device – to make and answer video calls with loved ones, friends and caregivers – MemoryAid users simply pick up the handset, a familiar action from a lifetime of practice, deeply ingrained in cognitive and muscle memory.
It was one of five international finalists in the Longitude Prize on Dementia – a global prize rewarding the development of assistive technologies for and with people living with dementia.
The £1 million grand prize was awarded to CrossSense, a revolutionary AI companion built into smart glasses to help people maintain their independence, in a ceremony last week.
But of course, it’s not just virtual connection that makes a difference to independence at home, physical safety matters too, especially in maintaining face-to-face relationships.
Enabling physical safety
A very different innovation, that also ran for the Longitude Prize on Dementia, is Theora360 – a wearable device to support people to live confidently at home without the fear of falling or wandering, enabling greater autonomy over their day to day lives.
Venturing outside independently can be difficult for people with cognitive impairments like dementia, with the fear of getting lost or falling and sustaining a serious injury presenting a barrier to leaving the house with confidence.
While most falls only result in minor injury, sometimes they can have a more serious impact – leading to a loss of mobility, independence and self-esteem.
Events such as hospitalisation and relocation can induce a range of negative experiences. A fall may cause someone to become home or bed-bound.
For someone with dementia, this may cause further distress as they may be unable to remember the cause of their injury or how to manage it effectively.
They are also more likely to experience worsening mental function as a result of pain or delirium.
If someone falls or wanders, Theora360 can alert a carer or loved one in real time, enabling rapid intervention. The sooner help can reach someone, it’s likely that the health consequences for them will be less severe.
The technology empowers people to retain agency over their social life, to go for their weekly coffee with a neighbour or visit the post office reassured that the support and assistance is there if they need it.
Facilitating meaningful moments
But where will AI take care next?
Solutions are continuously evolving.
The Theora 360 team, for example, is currently working with Texas A&M University to develop predictive capabilities based on changes in gait, to identify when a fall is likely and prevent it from happening in the first place.
There’s no doubt that technology is helping to shift the dial when it comes to combatting social isolation for people living with dementia.
By empowering people to remain independent, boosting confidence and helping to eliminate fear, AI can be a way to facilitate some of the most real and most meaningful moments between people.
Ruth Dixon is a Programme Lead at Challenge Works, a global leader in the design and delivery of open innovation challenge prizes for social good.
The Longitude Prize on Dementia is funded by Alzheimer’s Society and Innovate UK.
Gut-friendly foods may damage heart, charity warns
Diabetes patients face increased risk of undiagnosed heart failure
UK government announces £6.3m fund to boost men’s health
Brain health collaboratory launches in Gulf South
